NeoStem to Receive $700,000 from the U.S. Army's Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds
NEW YORK, July 12 /PRNewswire-Asia/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, today announced that it has been awarded a $700,000 contract from the U.S. Army Medical Research and Materiel Comm...
NeoStem to Present at the Global Hunter Securities China Conference in San Francisco on July 11 – 13, 2010
NEW YORK, July 10 /PRNewswire-Asia/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, today announced that Dr. Robin Smith, the Company's Chairman and CEO, has been invited by Global Hunter Securities...
NeoStem Named 'Best Stem Cell Company' in The New Economy's 2010 Biotech Awards
-- Recognizes NeoStem's pioneering work in adult stem cells, including development efforts relating to its VSEL(TM) Technology -- NEW YORK, July 6 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with ...
NeoStem Adds Distinguished Researcher to its World-Class Scientific Advisory Board
-- Dr. Roberto Bolli brings unmatched VSEL research expertise in the cardio niche -- -- Will help guide NeoStem's exciting VSEL(TM) technology R&D efforts -- NEW YORK, July 1 /PRNewswire-Asia/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutica...
NeoStem to Present at OneMedForum Emerging Company Finance Conference
NEW YORK, June 30 /PRNewswire-Asia/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced that the Company will present at the OneMedForum Emerging Company Finance Conference, hosted by OneMedPl...
NeoStem Pharmaceutical Subsidiary Announces Two cGMP Lines are Now Fully Operational in New Facility
Move increases production capacity by more than 50% for significant revenue generating antibiotics NEW YORK, June 29 /PRNewswire-Asia/ -- NeoStem, Inc. ("NeoStem" or the "Company") (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, announce...
NeoStem Achieves New Milestone as Company Joins Russell 3000 Index
NEW YORK, June 28 /PRNewswire-Asia/ -- NeoStem, Inc. ("NeoStem" or the "Company") (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, announced that it has been added to the broad-market Russell 3000 Index with Russell Investments' reconstitution o...
NeoStem Raises $5 Million in Registered Direct Offering
NEW YORK, June 26 /PRNewswire-Asia/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced today that the Company has entered into definitive agreements with certain accredited investors (the "...
Very Small Embryonic-Like Stem Cell Mobilization Data Presented at International Society for Stem Cell Research Annual Meeting
NEW YORK, June 17 /PRNewswire-Asia/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced today that a poster authored by NeoStem-affiliated scientists will be presented in a presentation at the...
NeoStem's Suzhou Erye Pharmaceutical Subsidiary Passes Government Inspection for Two Significant Manufacturing Lines in its New Facility
NEW YORK, June 15 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. ("NeoStem" or the "Company") (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, announced that its Suzhou Erye pharmaceutical subsidiary ("Erye") passed the government inspectio...
NeoStem Provides Business Update
Ratification of Deloitte & Touche LLP as independent registered public accounting firm Completed $2.5 million in financing NEW YORK, June 8 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operatio...
NeoStem Selected to Present at American Society for Apheresis
NEW YORK, May 28 /PRNewswire-Asia/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced that the Company's Director of Clinical Affairs and Apheresis, Lee Clough, BSN, RN, HP (ASCP), has been s...
NeoStem's Advanced Adult Stem Cell Technology to be Featured at Upcoming Conference
-- Company executives to discuss advances in autologous adult stem cells -- Rev. Tomasz Trafny of the Vatican's Pontifical Council for Culture will be a keynote speaker NEW YORK, May 28 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Co...
NeoStem to Ring Opening Bell at New York Stock Exchange on May 27, 2010
-- Celebrates key milestone, the recent collaboration with Vatican's Pontifical Council NEW YORK, May 26 /PRNewswire-Asia/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, today announced that...
NeoStem Announces Conversion of Convertible Preferred Stock by Principal Shareholder
NeoStem Shareholder Equity Increases by $13.7 million NEW YORK, May 20 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, is pleased to announce the conversion of Conve...
NeoStem Provides Update on its Pharmaceutical Subsidiary Suzhou Erye
NEW YORK, May 18 /PRNewswire-Asia/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, provided an update on its majority-owned pharmaceutical subsidiary Suzhou Erye (Erye) following the first quarter a...
NeoStem, Inc. to Present at NASDAQ MarketSite
Media and Investors are invited to NASDAQ MarketSite, New York City, Tuesday, May 25, 2010, 1:00 pm EDT NEW YORK, May 13 /PRNewswire-Asia/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, today an...
NeoStem, Inc. Officially Launches Adult Stem Cell Collection Center and R&D Laboratory in Cambridge, Massachusetts
NEW YORK, April 28 /PRNewswire-Asia/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, today announced the official launch of the Company's Adult Stem Cell Collection Center and Research & Development...
NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
NEW YORK and SCOTTSDALE, Ariz., April 22 /PRNewswire-Asia/ -- NeoStem, Inc. ("NeoStem") (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China and ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin B...
NeoStem's CEO Interviewed on NBC Affiliate KXAN Austin News
NEW YORK, April 21 /PRNewswire-Asia/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced today that Dr. Robin Smith, Chairman and CEO of NeoStem took part in an insightful interview with NBC a...
